More than 2.1 million shares of the stock had changed hands by 12:23 p.m., compared to the daily average volume of 285,730. The stock rose alongside fellow immunotherapy developer Juno Therapeutics (JUNO) , which soared to new highs on Monday just days after its IPO.
The FDA cleared Advaxis' Investigational New Drug application to begin a Phase 1/2 trial of ADXS-HPV to treat HPV-associated cervical cancer and HPV-associated head and neck cancer. Advaxis expects to begin patient enrollment in the trial in early 2015.
Exclusive Report: Jim Cramer’s Best Stocks for 2015ADXS data by YCharts